[Federal Register: May 8, 2003 (Volume 68, Number 89)]
[Notices]
[Page 24705-24706]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr08my03-25]
========================================================================
Notices
Federal Register
________________________________________________________________________
This section of the FEDERAL REGISTER contains documents other than rules
or proposed rules that are applicable to the public. Notices of hearings
and investigations, committee meetings, agency decisions and rulings,
delegations of authority, filing of petitions and applications and agency
statements of organization and functions are examples of documents
appearing in this section.
========================================================================
[[Page 24705]]
DEPARTMENT OF AGRICULTURE
Animal and Plant Health Inspection Service
[Docket No. 03-045-1]
Determination of Regulatory Review Period for Purposes of Patent
Extension; Fel-O-Vax[reg] FIV Vaccine
AGENCY: Animal and Plant Health Inspection Service, USDA.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: We are advising the public that the Animal and Plant Health
Inspection Service has determined the regulatory review period for Fel-
O-Vax[reg] FIV Vaccine and is publishing this notice of that
determination as required by law. We have made this determination in
response to the submission of an application to the Commissioner of
Patents and Trademarks, Department of Commerce, for the extension of a
patent that claims that veterinary biologic.
DATES: We will consider all requests for revision of the regulatory
review period determination that we receive on or before June 9, 2003.
We will consider all due diligence petitions that we receive on or
before November 4, 2003.
ADDRESSES: You may submit revision requests and due diligence petitions
by postal mail/commercial delivery or by e-mail. If you use postal
mail/commercial delivery, please send four copies of your request or
petition (an original and three copies) to: Docket No. 03-045-1,
Regulatory Analysis and Development, PPD, APHIS, Station 3C71, 4700
River Road Unit 118, Riverdale, MD 20737-1238. Please state that your
revision request or due diligence petition refers to Docket No. 03-045-
1. If you use e-mail, address your request or petition to
regulations@aphis.usda.gov. Your request or petition must be contained
in the body of your message; do not send attached files. Please include
your name and address in your message and ``Docket No. 03-045-1'' on
the subject line.
You may request a copy of the regulatory review period
determination by writing to Dr. Larry Ludemann, USDA, APHIS, VS, CVB-
LPD, 510 South 17th Street, Suite 104, Ames, IA 50010-8197, or by
calling (515) 232-5785. Please refer to the docket number, date, and
complete title of this notice when requesting copies.
A copy of the regulatory review period determination and any
revision requests or due diligence petitions that we receive on this
determination are available for public inspection in our reading room.
The reading room is located in room 1141 of the USDA South Building,
14th Street and Independence Avenue SW., Washington, DC. Normal reading
room hours are 8 a.m. to 4:30 p.m., Monday through Friday, except
holidays. To be sure someone is there to help you, please call (202)
690-2817 before coming.
APHIS documents published in the Federal Register, and related
information, including the names of organizations and individuals who
have commented on APHIS dockets, are available on the internet at
http://www.aphis.usda.gov/ppd/rad/webrepor.html.
FOR FURTHER INFORMATION CONTACT: Dr. Albert P. Morgan, Chief Staff
Officer, Operational Support Section, Center for Veterinary Biologics,
Licensing and Policy Development, VS, APHIS, 4700 River Road Unit 148,
Riverdale, MD 20737-1231; phone (301) 734-8245; fax (301) 734-4314. For
information regarding the regulatory review period determination,
contact Dr. Larry Ludemann, APHIS, VS, CVB-LPD, 510 South 17th Street,
Suite 104, Ames, IA 50010-8197; phone (515) 232-5785.
SUPPLEMENTARY INFORMATION: The provisions of 35 U.S.C. 156, ``Extension
of patent term,'' provide, generally, that a patent for a product may
be extended for a period of up to 5 years as long as the patent claims
a product that, among other things, was subject to a regulatory review
period before its commercial marketing or use. (The term ``product'' is
defined in that section as ``a drug product'' [which includes
veterinary biological products] or ``any medical device, food additive,
or color additive subject to regulation under the Federal Food, Drug,
and Cosmetic Act.'') A product's regulatory review period forms the
basis for determining the amount of extension an applicant may receive.
The regulations in 9 CFR part 124, ``Patent Term Restoration''
(referred to below as the regulations), set forth procedures and
requirements for the Animal and Plant Health Inspection Service's
(APHIS) review of applications for the extension of the term of certain
patents for veterinary biological products pursuant to 35 U.S.C. 156.
As identified in the regulations, the responsibilities of APHIS
include:
[sbull] Assisting Patent and Trademark Office of the U.S.
Department of Commerce in determining eligibility for patent term
restoration;
[sbull] Determining the length of a product's regulatory review
period;
[sbull] If petitioned, reviewing and ruling on due diligence
challenges to APHIS's regulatory review period determinations; and
[sbull] Conducting hearings to review initial APHIS findings on due
diligence challenges.
The regulations are designed to be used in conjunction with
regulations issued by the Patent and Trademark Office concerning patent
term extension, which may be found at 37 CFR 1.710 through 1.791.
A regulatory review period consists of two periods of time: A
testing phase and an approval phase. For veterinary biologics, the
testing phase begins on the date the authorization to prepare an
experimental veterinary biologic became effective and runs until the
approval phase begins. The approval phase begins on the date an
application for a license was initially submitted for approval and ends
on the date such license was issued. Although only a portion of a
regulatory review period may count toward the actual amount of
extension that the Commissioner of Patents and Trademarks may award,
APHIS' determination of the length of a regulatory review period for a
veterinary biologic will include all of the testing phase and approval
phase as specified in 35 U.S.C. 156(g)(5)(B).
APHIS recently licensed for production and marketing the veterinary
biologic Fel-O-Vax[reg] FIV Vaccine. Subsequent to this approval, the
Patent and Trademark Office received a patent term restoration
application for Fel-O-
[[Page 24706]]
Vax[reg] FIV Vaccine (U.S. Patent No. 5,275,813) from the
Regents of the University of California, and the Patent and Trademark
Office requested APHIS' assistance in determining this patent's
eligibility for patent term restoration. In a letter dated March 11,
2003, APHIS advised the Patent and Trademark Office that this
veterinary biologic had undergone a regulatory review period and that
the approval of Fel-O-Vax[reg] FIV Vaccine (Feline
Immunodeficiency Virus Vaccine, Killed Virus) represented the first
permitted commercial licensing or use of the product. Subsequently, the
Patent and Trademark Office requested that APHIS determine the
product's regulatory review period.
APHIS has determined that the applicable regulatory review period
for Fel-O-Vax[reg] FIV Vaccine is 3,853 days. Of this time,
2,442 days occurred during the testing phase of the regulatory review
period, and 1,411 days occurred during the approval phase. These
periods were derived from the following dates:
1. The date the authority to prepare an experimental biological
product under the Virus-Serum-Toxin Act (21 U.S.C. 151 et seq.) became
effective: August 28, 1991. APHIS has verified the applicant's claim
that the test was begun on August 28, 1991.
2. The date the application for a license was initially submitted
for approval under the Virus-Serum-Toxin Act: May 4, 1998. APHIS has
verified the applicant's claim that the application was initially
submitted on May 4, 1998.
3. The date the license was issued: March 14, 2002. APHIS has
verified the applicant's claim that the license for the commercial
marketing of the vaccine was issued on March 14, 2002.
This determination of the regulatory review period establishes the
maximum potential length of a patent extension. However, the U.S.
Patent and Trademark Office applies several statutory limitations in
its calculations of the actual period for patent extension. In its
application for patent extension, this applicant seeks 3,853 days of
patent term extension.
Section 124.22 of the regulations provides that any interested
person may request a revision of the regulatory review period
determination within 30 days of the date of this notice (see DATES
above). The request must specify the following:
[sbull] The identity of the product;
[sbull] The identity of the applicant for patent term restoration;
[sbull] The docket number of this notice; and
[sbull] The basis for the request for revision, including any
documentary evidence.
Further, under Sec. 124.30 of the regulations, any interested
person may file a petition with APHIS, no later than 180 days after the
date of this notice (see DATES above), alleging that a license
applicant did not act with due diligence in seeking APHIS approval of
the product during the regulatory review period. The filing, format,
and content of a petition must be as described in the regulations in
``Subpart D--Due Diligence Petitions'' (Sec. Sec. 124.30 through
124.33).
Authority: 35 U.S.C. 156.
Done in Washington, DC, this 1st day of May 2003.
Peter Fernandez,
Acting Administrator, Animal and Plant Health Inspection Service.
[FR Doc. 03-11436 Filed 5-7-03; 8:45 am]
BILLING CODE 3410-34-P